Clinical Research Directory
Browse clinical research sites, groups, and studies.
6 clinical studies listed.
Filters:
Tundra lists 6 Subcutaneous Fat clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.
This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.
NCT07526974
A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 )
A phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat.
Gender: All
Ages: 18 Years - Any
Updated: 2026-10-20
14 states
NCT07608770
A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat
A phase 2b, randomized, placebo-controlled study with long-term re-treatment to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat
Gender: All
Ages: 18 Years - Any
Updated: 2026-10-20
1 state
NCT07608757
A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat
A phase 2b, randomized, placebo-controlled study with long-term re-treatment to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat.
Gender: All
Ages: 18 Years - Any
Updated: 2026-10-20
1 state
NCT07140939
A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat
A phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat.
Gender: All
Ages: 18 Years - Any
Updated: 2026-10-19
13 states
NCT07733947
A Study to Evaluate the Maintenance of Efficacy and Long-term Safety of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)
A Phase 3b, Multicenter, Two stage, Double-blind, Long term Follow up and Open-label Extension Study of Participants Who have Completed the CBL-0301 or CBL-0302 Study for Reducing Abdominal Subcutaneous Fat (Stage 1)
Gender: All
Ages: 18 Years - Any
Updated: 2026-10-19
1 state
NCT05234736
A Study to Evaluate the Pharmacokinetic Profile of CBL-514 Injection in Healthy Volunteers
This Phase 2 study will be an open-label and single course study to assess the safety, tolerability, PK and metabolite profile of CBL-514.
Gender: All
Ages: 18 Years - 64 Years
Updated: 2026-05-22
1 state